Robert Andtbacka Discusses T-VEC Trials
Robert Andtbacka, MD, associate professor, Division of Surgical Oncology Department of Surgery, University of Utah School of Medicine, discusses past, present, and future trials for T-VEC.
Robert Andtbacka on Managing Side Effects From T-VEC
Robert Andtbacka, MD, from University of Utah School of Medicine, discusses the management of side effects from T-VEC.
Neoadjuvant Pembrolizumab Improves pCR Across ER+ Breast Cancer Subgroups
Tucatinib Continues to Show Benefit in Pretreated HER2+ Breast Cancer With Brain Metastases
Ribociclib Plus Endocrine Therapy Continues to Perform Well Across MONALEESA-2, -3, and -7 Trials
Patient-Reported Outcomes From CAPItello-291 Trial Support Capivasertib/Fulvestrant in HR+, HER2- Advanced Breast Cancer
2 Clarke Drive Cranbury, NJ 08512